New hope for brain lymphoma patients with targeted drug cocktail
NCT ID NCT07410520
First seen Feb 14, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This study tests a combination of four drugs (PD-1 inhibitor, rituximab, methotrexate, and orelabrutinib) in 50 adults with newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this treatment can stop the cancer from growing for at least one year. Participants will receive the drugs intravenously and by mouth, and their progress will be monitored with MRI scans and follow-up visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.